PRIME Dry Spell Ends As EMA Takes On Eye Disease Gene Therapy
The first designation of 2018 under the European Medicines Agency’s PRIME scheme has gone to an advanced therapy for patients with the severe eye disorder, achromatopsia. In the meantime, most PRIME applications are still getting rejected.
You may also be interested in...
IPO Update: Returns Rebound As June Sees Its First New Biopharma Offering
MeiraGTx was the first to go public in the US in June after six drug developer IPOs launched in May. With returns for this year's first-time biopharma offerings more than doubling from 9% at the end of April to 23.6% as of June 8, four new companies have filed and six have set terms for future IPOs.
Finance Watch: Six More IPO Filings As Three More Biopharmas Go Public In The US
Public Company Edition: Kiniksa, Scholar Rock and Iterum launch the most recent US IPOs and at least five more drug developers join the queue. Also, Polyphor go public in Switzerland, Valeant and Ligand sell notes, and MyoKardia led recent follow-on offerings.
EMA’s PRIME Is Driving Innovation, But Too Early To Tell If Drugs Will Reach Patients Faster
With just three marketing applications filed, the European Medicines Agency says it is too soon to say whether PRIME, its priority medicines scheme, is meeting its objective. The agency is satisfied, though, that the scheme has started to drive innovation.